Humacyte (HUMA) Share-based Compensation (2020 - 2026)
Humacyte (HUMA) posted quarterly Share-based Compensation of $21.0 million for Q1 2026, up 744.39% year-over-year from $2.5 million in Q1 2025, and up 388.34% quarter-over-quarter from -$7.3 million in Q4 2025.
Humacyte (HUMA) Share-based Compensation (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Share-based Compensation for 7 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 744.39% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $21.0 million (up 1106.2% YoY), while the FY2025 annual figure was $23.5 million, up 3219.21% from the prior year.
- Share-based Compensation improved to $21.0 million in Q1 2026 per HUMA's latest filing, from -$7.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $21.0 million in Q1 2026 and bottomed at -$7.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged $2.1 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 347.29% — and 2026, when it surged 744.39%.
- Humacyte's Share-based Compensation stood at $1.7 million in 2022, then surged by 308.86% to $6.8 million in 2023, then sank by 154.7% to -$3.7 million in 2024, then plunged by 94.99% to -$7.3 million in 2025, then jumped by 388.34% to $21.0 million in 2026.
- Business Quant data shows HUMA's Share-based Compensation at $21.0 million in Q1 2026, -$7.3 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 17.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.70 Mn |
| Jun 30, 2026 | 17.70 Mn |
| Mar 31, 2026 | 21.00 Mn |
| Mar 31, 2026 | 21.00 Mn |
| Dec 31, 2025 | -7.28 Mn |
| Dec 31, 2025 | -7.28 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | -3.74 Mn |
| Dec 31, 2024 | -3.74 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |